APA (7th ed.) Citation

Yuan Hong, Xichuang Chen, Yuanquan Hong, Xingfang Xiao, Yan Wang, Xiaohong You, . . . Zhihu Huang. (2023). Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: A lifetime economic research study. BMC.

Chicago Style (17th ed.) Citation

Yuan Hong, et al. Ibrutinib Versus Bendamustine Plus Rituximab for First-line Treatment of 65 or Older Patients with Untreated Chronic Lymphocytic Leukemia Without Del(17p)/TP53 Mutation in China: A Lifetime Economic Research Study. BMC, 2023.

MLA (9th ed.) Citation

Yuan Hong, et al. Ibrutinib Versus Bendamustine Plus Rituximab for First-line Treatment of 65 or Older Patients with Untreated Chronic Lymphocytic Leukemia Without Del(17p)/TP53 Mutation in China: A Lifetime Economic Research Study. BMC, 2023.